The Gynecologic Oncology Group (GOG) is the foremost multi-disciplinary cooperative clinical trial research group devoted to the study of gynecologic malignancies. Since its inception in 1970, the GOG has been a recognized leader in the development of new forms of treatment and has relied on the phase III trial as the design to identify new information. Supporting that major activity are the concerted efforts of modality committees providing recent approaches and procedures in each of the relevant diagnostic and therapeutic disciplines. The GOG has an active, effective program in the study of new chemotherapeutic agents in gynecologic cancers and this program has introduced important findings for study in the Phase III setting. In patients with advanced cervical, endometrial and ovarian cancers, the GOG has defined significant improvement associated with the use of cisplatin. The GOG has performed a series of trials to examine the role of paclitaxel either as a single agent or in combination with other agents. Isofamide was found to be one of the most active single agents in squamous carcinoma of the cervix. The results of Phase III studies by the GOG have provided a new standard of treatment in suboptimal ovarian cancer using platin and taxol. Two recently completed trials of post-operative patients with intermediate risk endometrial and cervical cancer showed a significant improvement with adjuvant radiotherapy. The benefit of post-operative adjuvant chemotherapy has been confirmed for patients with totally resected, early stage ovarian cancer. In addition, the GOG has been active in developing new mechanisms to enhance translational research, cancer prevention and control and medical informatics. The Group has collaborative actively with the NCI in evaluating new data management collection and reporting systems. After more than 25 years, the GOG continues to be foremost in developing new strategies in the management of these cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA027469-21
Application #
6375621
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1980-05-01
Project End
2004-03-31
Budget Start
2001-04-01
Budget End
2002-03-31
Support Year
21
Fiscal Year
2001
Total Cost
$8,400,805
Indirect Cost
Name
American College of Ob and Gyn
Department
Type
DUNS #
076890524
City
Washington
State
DC
Country
United States
Zip Code
20024
Matulonis, Ursula A; Sill, Michael W; Makker, Vicky et al. (2018) A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol :
Boardman, Cecelia H; Brady, William E; Dizon, Don S et al. (2018) A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic On Gynecol Oncol 151:202-207
Felix, Ashley S; Cohn, David E; Brasky, Theodore M et al. (2018) Receipt of adjuvant endometrial cancer treatment according to race: anĀ NRG Oncology/Gynecologic Oncology Group 210 Study. Am J Obstet Gynecol 219:459.e1-459.e11
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Cosgrove, Casey M; Tritchler, David L; Cohn, David E et al. (2018) An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecol Oncol 148:174-180
Gee, Michael S; Atri, Mostafa; Bandos, Andriy I et al. (2018) Identification of Distant Metastatic Disease in Uterine Cervical and Endometrial Cancers with FDG PET/CT: Analysis from the ACRIN 6671/GOG 0233 Multicenter Trial. Radiology 287:176-184
Olawaiye, Alexander B; Java, James J; Krivak, Thomas C et al. (2018) Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 151:18-23
Hamilton, C A; Miller, A; Casablanca, Y et al. (2018) Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study. Gynecol Oncol 148:275-280
Norquist, Barbara M; Brady, Mark F; Harrell, Maria I et al. (2018) Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res 24:777-783
Chan, John K; Brady, William; Monk, Bradley J et al. (2018) A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). Gynecol Oncol 150:247-252

Showing the most recent 10 out of 519 publications